« Return to News | R&D Trends

Gliknik, Pfizer enter autoimmune disease licensing agreement

Monday, September 30, 2013 02:44 PM

Gliknik, a privately-held biopharmaceutical company, has entered into an exclusive worldwide licensing agreement with Pfizer for GL-2045, Gliknik's recombinant stradomer, a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). GL-2045 has shown promising results in preclinical tests and is being developed as a potential treatment for a wide variety of autoimmune diseases, including those in which IVIG is clinically used.

Pfizer will receive an exclusive worldwide license to GL-2045 for all therapeutic indications. Gliknik will receive an upfront payment of $25 million and is eligible to receive development, regulatory and commercial milestone payments. Gliknik also is eligible to receive tiered, double-digit royalties on net sales of any products commercialized.

"People with certain autoimmune diseases have limited treatment options, difficult regimens and, often, a poor prognosis," said Jose Carlos Gutierrez-Ramos, Ph.D., group senior vice president and head of biotherapeutics R&D at Pfizer. "Pooled IVIG has a long history of use but has a number of limitations."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.